Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. [electronic resource]
Producer: 20000328Description: 406-14 p. digitalISSN:- 1078-0432
- Adult
- Aged
- Anemia -- etiology
- Antibodies, Monoclonal -- adverse effects
- Biotin -- administration & dosage
- Colonic Neoplasms -- pathology
- Female
- Humans
- Leukopenia -- etiology
- Male
- Middle Aged
- Neoplasm Metastasis
- Organometallic Compounds -- administration & dosage
- Radioimmunotherapy
- Radiopharmaceuticals -- adverse effects
- Thrombocytopenia -- etiology
- Yttrium Radioisotopes -- adverse effects
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.